Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Sarcoma × balstilimab × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 6 Pancreatic Neoplasms 4 Stomach Neoplasms 2 Rectal Neoplasms 2 Colonic Neoplasms 2 Urinary Bladder Neoplasms 1 Sarcoma 1 Resectable MMR-deficient Solid Tumors 1 Pancreatic Cancer Metastatic 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Microsatellite Stable Rectal Carcinoma 1 Lymphoma 1 Esophageal Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Cancer Metastatic 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Advanced Renal Cell Carcinoma 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

Doxorubicin 57 Radiotherapy 40 Ifosfamide 39 Gemcitabine 37 Cyclophosphamide 29 Docetaxel 24 pazopanib 23 Filgrastim 22 pembrolizumab 21 Nivolumab 20 Trabectedin 19 Etoposide 18 Cisplatin 17 Surgical Procedures, Operative 16 Blood Specimen Collection 15 Radiation 12 Carboplatin 12 liposomal doxorubicin 11 Ipilimumab 11 apatinib 10 anlotinib 10 Vincristine 10 Radiosurgery 10 Peripheral Blood Stem Cell Transplantation 10 Melphalan 10 Magnetic Resonance Spectroscopy 10 Drug Therapy 10 Bevacizumab 10 Temozolomide 9 Sorafenib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04028063 2026-01-27

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

University of Colorado, Denver

Phase 2 Recruiting

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡